A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.

Trial Profile

A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mipomersen (Primary) ; Mipomersen (Primary)
  • Indications Atherosclerosis; Bacterial infections; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Dec 2015 Results published in the European Journal of Clinical Pharmacology
    • 16 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Actual patient number is 60 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top